What do systematic reviews say?

Rituximab vs placebo

Rituximab as 'first choice' showed no clear difference in cancer measured by clinical assessment over 28 months compared with placebo (low certainty).

• Rituximab for people with multiple sclerosis 2021 · Cochrane Headline outcomes only
  OR 0.5 [0.07, 3.59]
  1 study · 439 participants
  Low